Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02048163

Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

A Comparison of the Effect of Intermittent and Continuous Infusion of Meropenem on the Prevalence of Nausea in Pediatric Cystic Fibrosis Patients

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Dayton Children's Hospital · Academic / Other
Sex
All
Age
7 Years – 21 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.

Detailed description

1. To assess the number of episodes of emesis following both short and prolonged intermittent infusion of meropenem. 2. To assess the number of episodes of emesis corresponding to the peak serum concentration of meropenem. 3. To assess the number of episodes of emesis corresponding to the area under the meropenem serum concentration time curve. 4. To assess reported nausea, measured through administered dosages of anti-nausea medication, following both short and prolonged intermittent infusion of meropenem. 5. To assess reported nausea, measured through administered doses of anti-nausea medication, corresponding to peak concentrations of meropenem. 6. To assess reported nausea, measured through administered dosages of anti-nausea medication, corresponding to the area under the serum concentration time curve 7. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity of nausea in pediatric patients, following both short and prolonged intermittent infusion of meropenem. 8. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity corresponding to the peak serum concentrations of meropenem. 9. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity corresponding to the area under the meropenem serum concentration time curve.

Conditions

Timeline

Start date
2013-12-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2014-01-29
Last updated
2016-02-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02048163. Inclusion in this directory is not an endorsement.